References
- Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J. L., Maloisel F., Bouabdallah R., Guyotat D., Cheron N., Nicolini F., Abgrall J. F., Tanzer J. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine 1997; 337: 223–229
- Kantarjian H. M., Keating M. J., Estey E. H., O'Brien S., Pierce S., Beran M., Koller C., Peldman E., Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of Clinical Oncololgy 1992; 10: 772–778
- Perrajoli A., Liberati A. M., Caricchi P., Donti E., Morra E., Lazzarino M., Betti A. R., Bernasconi P., Saglio G. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European Journal of Haematology 1995; 55: 184–188
- Thaler J., Hilbe W., Apfelbeck U., Linkesch W., Sill H., See-Wann H., Pont J., Bernhart M., Stoger M., Niessner H., Abbrederis K., Geissler D., Hausmaninger H., Lin W., Ludwig H., Lang A., Duba C., Pluckinger T., Greil R., Grunewald K., Konwalinka G., Niederwieser D., Fridrik M. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Leukemia Research 1997; 21: 75–80
- Foss F. M., Ihde D. C., Linnoila I. R., Pischmann A. B., Schechter G. P., Cotelingam J. D., Steinberg S. M., Ghosh B. C., Stacker J. L., Bastian A., Phares J. C., Sausville E. A. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. Journal of Clinical Oncology 1994; 12: 2051–2059
- Hoffmann A., Kirn P., Krueger G. R. F., Fischer R. Bone marrow hypoplasia and fibrosis following interferon treatment. In vivo 1994; 8: 605–612
- Talpaz M., Kantarjian H., Kurzrock R., Gutterman J. U. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer 1992; 69: 410–412
- Shepherd P. C. A., Richards S., Allan N. C. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. British Journal of Haematology 1994; 86: 92–96
- Pattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology 1996; 24: 38–47
- Maciejewski J. P., Selleri C., Sato T., Anderson S., Young N. S. Increased expression of Pas antigen on bone marrow CD34+ cells of patients with aplastic anemia. British Journal of Hematology 1995; 91: 245–252
- Zoumbos N. C., Gascon P., Djeu J. Y., Young N. S. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proceedings of the National Academy of Sciences USA 1985; 82: 188–192
- Binder D., Van den Broek M. F., Kagi D., Bluethmann H., Fehr J., Hengartner H., Zinkernagel R. M. Aplastic anemia rescued by exhaustion of cytokine-secreting VD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. Journal of Experimental Medicine 1998; 187: 1903–1920
- Kimura Y., Kajiyama K., Nomura H., Shiraishi G. Severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C associated with systemic lupus erythematosus. Fukuoka Igaku Zasshi 1994; 85: 329–333
- Siciliano R., Trovato B. A., Seminara G., Giustolisi V., Malaguarnera M. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int. 1995; 10: 193–194
- Mangan K. P., Zidar B., Shadduck R. K., Zeigler Z., Winkelstein A. Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin. American Journal of Hematology 1985; 19: 401–413